Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 2beta-Thalassemia 1Obesity 1Neoplasms 1Hepatoblastoma 1Endobronchial Metastases 1

Interventions

Cisplatin 8Carboplatin 8X-Rays 7Specimen Handling 7Phantoms, Imaging 7Magnetic Resonance Spectroscopy 6Cyclophosphamide 6sodium thiosulfate 5Vincristine 5Nuclear Medicine Department, Hospital 5Granulocyte Colony-Stimulating Factor 5Etoposide 5Doxorubicin 5Biopsy 5Melphalan 4Irinotecan 4Fluorouracil 4fludarabine 3Thiotepa 3Oxaliplatin 3Mesna 3Gemcitabine 3Filgrastim 3Busulfan 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2pembrolizumab 2palbociclib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hepatoblastoma × Sugammadex × Gastrointestinal × Clear all
NCT03728543 2018-11-02

the Efficacy and Safety of Sugammadex in Children 0-2 Years Old

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 2/3 Unknown
62 enrolled
Gastrointestinal

Neoplasms, beta-Thalassemia, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡